Shire North American Group Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$213.3M
Doctors Paid
91,193
Transactions
477,458
2019 Total
$62.2M
Payment Breakdown by Category
Research$145.3M (68.1%)
Consulting$17.3M (8.1%)
Royalty/License$13.5M (6.3%)
Food & Beverage$9.2M (4.3%)
Travel$5.0M (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $145.3M | 23,173 | 68.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18.8M | 7,844 | 8.8% |
| Consulting Fee | $17.3M | 7,209 | 8.1% |
| Royalty or License | $13.5M | 69 | 6.3% |
| Food and Beverage | $9.2M | 413,793 | 4.3% |
| Travel and Lodging | $5.0M | 19,420 | 2.4% |
| Grant | $2.6M | 45 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $1.0M | 334 | 0.5% |
| Education | $225,789 | 5,564 | 0.1% |
| Charitable Contribution | $183,500 | 6 | 0.1% |
| Gift | $14.99 | 1 | 0.0% |
Payments by Type
Research
$145.3M
23,173 transactions
General
$68.0M
454,285 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, PLACEBO-CONTROLLED, RW | $9.7M | 0 | 1,154 |
| AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT | $9.0M | 2 | 365 |
| TARGETING GASTROINTESTINAL EPITHELIAL INTEGRITY WITH GLUCAGON-LIKE PEPTIDE 2 ANALOG TO REDUCE DETRIMENTAL IMMUNE ACTIVATION AND ARTERIAL INFLAMMATION | $6.2M | 0 | 2 |
| A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF SHP626, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR ASBTI IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH | $5.8M | 0 | 537 |
| HELP Study ExtensionTM An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema HAE | $4.8M | 0 | 532 |
| A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTIONS THAT ARE RESISTANT OR REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR IN TRANSPLANT RECIPIENTS | $4.5M | 6 | 614 |
| ORAL BUDESONIDE SUSPENSION OBS IN ADOLESCENTS AND ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS DB, MAINTENANCE | $3.7M | 0 | 635 |
| Oral Budesonide Suspension OBS in Adolescent and Adult Subjects 11 to 55 Years of Age, Inclusive With Eosinophilic Esophagitis A Phase 3 Randomized, Double-blind, Placebo-controlled Study | $3.7M | 0 | 371 |
| HIPS - HEMOPHILIA INHIBITOR PUP STUDY | $3.6M | 0 | 12 |
| A PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WITH SHORT BOWEL SYNDROME WHO PARTICIPATED IN TED-C14-006 | $3.4M | 0 | 452 |
| HELP STUDY EXTENSIONTM AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DX-2930 FOR PREVENTION AGAINST ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA HAE | $3.3M | 0 | 454 |
| HELP STUDY EXTENSION AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DX-2930 FOR PREVENTION AGAINST ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA HAE | $2.9M | 0 | 371 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PARALLEL-GROUP, PLACEBO-CONTROLLED, FIXED-DOSE SAFETY AND EFFICACY STUDY OF SPD489 COMPARED WITH PLACEBO IN PRESCHOOL CHILDREN AGED 4-5 YEARS WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER | $2.8M | 0 | 465 |
| A RANDOMIZED, OPEN-LABEL, SINGLE-DOES, PHASE I STUDY TO ASSESS THE BIOAVAILABILITY OF LANADELUMAB ADMINISTERED SUBCUTANEOUSLY WITH THE PRE-FILED SYRINGE AND THE AUTO INJECTOR IN HEALTHY ADULT VOLUNTEER SUBJECTS. | $2.3M | 0 | 10 |
| SAFETY AND TOLERABILITY STUDY OF SHP465 IN CHILDREN AGED 4 TO 12 YEARS DIAGNOSED WITH ATTENTION-DEFICITHYPERACTIVITY DISORDER ADHD | $2.3M | 1 | 432 |
| A CONTROLLED, RANDOMIZED, TWO-ARM, OPEN-LABEL, ASSESSOR-BLINDED, MULTICENTER STUDY OF INTRATHECAL IDURSULFASE-IT ADMINISTERED IN CONJUNCTION WITH INTRAVENOUS ELAPRASE IN PEDIATRIC PATIENTS WITH HUNTER SYNDROME AND EARLY COGNITIVE IMPAIRMENT | $2.2M | 0 | 51 |
| A PHASE 3, OPEN-LABEL, MULTICENTER, 12-MONTH SAFETY AND TOLERABILITY STUDY OF SPD489 IN PRESCHOOL CHILDREN AGED 4-5 YEARS DIAGNOSED WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER | $2.1M | 0 | 507 |
| An Open Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase in Pediatric Patients With Hunter Syndrome and Cognitive Impairment | $2.0M | 0 | 36 |
| A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF SHP640 PVP-IODINE 0.6 AND DEXAMETHASONE 0.1 OPHTHALMIC SUSPENSION COMPARED TO PLACEBO IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS | $1.9M | 6 | 381 |
| RANDOMIZED COMPARISON OF FIXED DOSING VS. PHARMACOKINETICALLY GUIDED DOSE-ADJUSTED ADMINISTRATION OF PEGASPARGASE IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ALL | $1.9M | 0 | 10 |
| EXTENDED USE OF RECOMBINANT HUMAN PARATHYROID HORMONE RHPTH1-84 IN HYPOPARATHYROIDISM | $1.8M | 1 | 145 |
| A RETROSPECTIVE AND PROSPECTIVE, OPEN LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF TEDUGLUTIDE IN PEDIATRIC PATIENTS WITH SHORT BOWEL SYNDROME WHO PARTICIPATED IN TED-C13-003 | $1.8M | 0 | 254 |
| A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | $1.7M | 0 | 1,733 |
| AN OPEN-LABEL EXTENSION TO STUDY HGT-HIT-045 EVALUATING LONG-TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL ADMINISTRATION OF IDURSULFASE-IT IN PEDIATRIC PATEINTS WITH HUNTER SYNDROME WHO DEMONSTRATE EVIDENCE OF CENTRAL NERVOUS SYSTEM INVOLVEMENT AND | $1.7M | 0 | 58 |
| EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY AND PHARMACOKINETIC EVALUATION OF HYQVIA IN PEDIATRIC PIDD SUBJECTS | $1.6M | 1 | 916 |
| A 24-WEEK DOUBLE-BLIND, SAFETY, EFFICACY, AND PHARMACODYNAMIC STUDY INVESTIGATING TWO DOSES OF TEDUGLUTIDE IN PEDIATRIC SUBJECTS THROUGH 17 YEARS OF AGE WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT | $1.6M | 0 | 1,525 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO VALGANCICLOVIR FOR THE TREATMENT OF CYTOMEGALOVIRUS CMV INFECTION IN STEM CELL TRANSPLANT RECIPIENTS | $1.5M | 1 | 246 |
| Randomized Study of Intravenous Calaspargase Pegol SC-PEG Asparaginase and Intravenous Oncaspar in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | $1.5M | 0 | 2 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CINRYZE C1 ESTERASE INHIBITOR HUMAN FOR THE TREATMENT OF ACUTE ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANT PATIENTS | $1.5M | 13 | 473 |
| MECHANISMS UNDERLYING CARDIOVASCULAR EFFECTS OF ARBNEP INHIBITION AIM 2 | $1.4M | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Sunir Joshi, M.d, M.D | Ophthalmology | Ft Lauderdale, FL | $911,966 | $0 |
| Dr. Raffi Tachdjian, M.d, M.D | Pediatric Allergy/Immunology | Santa Monica, CA | $547,985 | $0 |
| Dr. William Lumry, M.d, M.D | Specialist | Dallas, TX | $540,154 | $0 |
| David Ginsburg, Md, MD | Internal Medicine | Ann Arbor, MI | $438,230 | $0 |
| Autumn Burnette, Md, MD | Allergy & Immunology | Washington, DC | $364,095 | $0 |
| Tammuella Chrisentery-Singleton, Md, MD | Pediatric Hematology-Oncology | New Orleans, LA | $344,321 | $0 |
| Michael Manning, Md, MD | Allergy & Immunology | Scottsdale, AZ | $342,119 | $0 |
| Dr. Alberto Santiago Cornier, M.d, M.D | Clinical Genetics (M.D.) | Santurce, PR | $334,380 | $0 |
| Douglas Johnston, Do, DO | Allergy & Immunology | Greenville, SC | $306,781 | $0 |
| Whitney Hauser, O.d, O.D | Optometrist | Memphis, TN | $299,666 | $0 |
| Dr. Jay Kashkin, Md, MD | Allergy | Fair Lawn, NJ | $283,563 | $0 |
| Dr. Joshua Jacobs, Md, MD | Allergy & Immunology | Walnut Creek, CA | $281,471 | $0 |
| Mark Glaum, M.d., Ph.d, M.D., PH.D | Allergy & Immunology | Tampa, FL | $270,939 | $0 |
| Dr. Steven Kang, Md, MD | Blood Banking & Transfusion Medicine | Brooklyn, NY | $264,881 | $0 |
| Dr. Humam Farah, M D, M D | Critical Care Medicine | Hannibal, MO | $262,690 | $0 |
| Marc Riedl, Md, MD | Allergy & Immunology | San Diego, CA | $258,857 | $0 |
| Derek Cunningham, O.d, O.D | Optometrist | Austin, TX | $252,748 | $0 |
| Myron Liebhaber, M.d, M.D | Allergy & Immunology | Santa Barbara, CA | $239,866 | $0 |
| Dr. Paul Karpecki, Od, OD | Optometrist | Lexington, KY | $234,133 | $0 |
| David Kaufman, M.d, M.D | Allergy & Immunology | Shreveport, LA | $228,281 | $0 |
| Richard Vetter, Md, MD | Family Medicine | West Fargo, ND | $224,391 | $0 |
| Dr. Muhammad Sethi, M.d., M.b;B.s, M.D., M.B;B.S | Endocrinology, Diabetes & Metabolism | Tucson, AZ | $223,206 | $0 |
| Douglas Devries, O.d, O.D | Optometrist | Sparks, NV | $216,467 | $0 |
| Dr. John Bilezikian, M.d, M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $214,623 | $0 |
| Doris Quon, M.d, M.D | Hematology | Los Angeles, CA | $204,776 | $0 |
Ad
Top Products
- GATTEX $17.0M
- XIIDRA $13.7M
Associated Products (18)
- XIIDRA $18.4M
- TAKHZYRO $15.1M
- CINRYZE $11.6M
- VYVANSE $10.2M
- ADVATE $8.6M
- MYDAYIS $7.3M
- NATPARA $5.3M
- CUVITRU $4.7M
- GLASSIA $3.9M
- VPRIV $3.8M
- NATPARA (PARATHYROID HORMONE) $3.3M
- ADYNOVATE $2.7M
- LIALDA $1.6M
- RECOMBINATE $476,966
- KALBITOR $281,308
- FOSRENOL $171,097
- GAMMAGARDKIOVIG $18,273
- PENTASA $12,259
Payment Categories
- Food & Beverage $9.2M
- Consulting $17.3M
- Travel & Lodging $5.0M
- Research $145.3M
- Royalties $13.5M
About Shire North American Group Inc
Shire North American Group Inc has made $213.3M in payments to 91,193 healthcare providers, recorded across 477,458 transactions in the CMS Open Payments database. In 2019, the company paid $62.2M. The top product by payment volume is GATTEX ($17.0M).
Payments were distributed across 252 medical specialties. The top specialty by payment amount is Ophthalmology ($7.5M to 7,504 doctors).
Payment categories include: Food & Beverage ($9.2M), Consulting ($17.3M), Research ($145.3M), Travel & Lodging ($5.0M), Royalties ($13.5M).
Shire North American Group Inc is associated with 18 products in the CMS Open Payments database, including XIIDRA, TAKHZYRO, and CINRYZE.